Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT05187312
Recruiting Observational

Registry for Advanced Endoscopy

NCT05187312 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Stockholm
Phase
Observational
Started
2022-01-14
Last updated
2024-04-12

Condition(s) studied

CholangiocarcinomaPancreatic CancerSclerosing Cholangitis

Investigational drug(s) / intervention(s)

Endoscopic retrograde Cholangio- pancreatographyEndoscopic ultrasound

Endoscopic retrograde Cholangio- pancreatography: Endoscopic intervention in the biliary or pancreatic duct

Endoscopic ultrasound: Endoscopic investigation/intervention with ultrasound

Study summary

Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical indication for endoscopic intervention/procedure Exclusion Criteria: * No informed consent * Age \<18 years

Primary outcome measure(s)

  • Adverse events — 30-days and 60-days post-procedure
    Incidence of Adverse events following endoscopic procedures. Measured as percentage of individuals with an adverse event
  • Diagnostic yield — 1-year follow up
    Diagnostic yield after tissue sampling

Trial sites (1)

FacilityCityRegionStatus
Karolinska University Hospital Stockholm Sweden Recruiting

More Region Stockholm trials in Sweden

Clinical Outcomes and Equality in Healthcare for Emergency General Surgery Patients Undergoing Emergency Laparotomy Recruiting
Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult Recruiting
Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy Starting soon
Identification of Interpesonal Violence Recruiting
TRIOCOL - The Study of Continued Advanced Medical Therapy or Colectomy in Patients With Ulcerative Colitis Recruiting

Other trials for the same condition

The Dragon PLC Trial (DRAGON-PLC) Recruiting
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Active, not recruiting
Pancreatic Cancer Initial Detection Via Liquid Biopsy Enrolling by invitation
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer Recruiting
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05187312 on ClinicalTrials.gov ↗ ← All trials in Sweden